Intravenous formulation and lc/ms/ms analysis method for gmc1
AssigneesBoard of Regents, The University of Texas System, Texas Southern University
InventorsMarc Cox, Huan Xie, Oscar Ekpenyong
Life of this patent
Estimating the term…
Abstract
Certain embodiments are directed to a GMC1 co-solvent formulation. The GMC1 co-solvent formulation described herein can be used for the treatment of prostate cancer, benign prostatic hypertrophy, and other hormone-related conditions involving androgen, glucocorticoid, and progesterone receptors.
Claims12
A co-solvent formulation comprising (i) 20 to 80% PEG 300, (ii) 20 to 80% Labrasol® and (iii) 1 to 200 mg/mL GMC1.
A method of treating prostate cancer comprising administering to a subject having prostate cancer a formulation comprising (i) 20 to 80% PEG 300, (ii) 20 to 80% Labrasol® and (iii) 1 to 200 mg/mL GMC1.
A method for assessing GMC1 in a sample comprising:
- (a) separating GMC1 containing sample using liquid chromatography (LC) over a C18 column with a binary solvent system, the solvent system comprising a first solvent of 0.1-2% formic acid in water and a second solvent of 0.1-2% formic acid in methanol;
- (b) collecting LC fractions for analysis by mass spectrometry;
- (c) introducing collected fraction(s) into a mass spectrometer for multiple reaction monitoring (MRM) detection of ions produced from GMC1 in the collected fractions;
- and
- (d) detecting ions produced from ionization of GMC1.
Dependencies are inferred from the claim text.